AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32410305 — intervention group
Group type: COMPARATOR
Intervention: Parents without depressive symptoms
Number of subjects: 128
Study 32410526 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit vessels
Number of subjects: 115
Study 32410526 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-culprit vessels
Number of subjects: 115
Study 32410532 — intervention group
Group type: EXPERIMENTAL
Intervention: Caraway extract, consumed during a ninety days clinical trial.
Number of subjects: 0
Study 32410532 — intervention group
Group type: EXPERIMENTAL
Intervention: ANFIS-PSO analysis method.
Number of subjects: 0
Study 32410617 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based personalized robot-aided rehabilitation therapy
Number of subjects: 19
Study 32410668 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional training unit (intervention group)
Number of subjects: 252
Study 32410668 — intervention group
Group type: COMPARATOR
Intervention: Conventionally organized ward (comparison group)
Number of subjects: 252
Study 32410670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy (DBT) implementation
Number of subjects: 82
Study 32411082 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Number of subjects: 0
Study 32411082 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32411374 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week supervised heavy resistance training program with weekly undulating periodization
Number of subjects: 25
Study 32411381 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation group therapy (BA) in addition to usual care
Number of subjects: 20
Study 32411381 — intervention group
Group type: COMPARATOR
Intervention: Support group in addition to usual care
Number of subjects: 20
Study 32411388 — intervention group
Group type: COMPARATOR
Intervention: PPV without ILM peeling (Group A)
Number of subjects: 60
Study 32411388 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV with ILM peeling (Group B)
Number of subjects: 60
Study 32411431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injections
Number of subjects: 26
Study 32411640 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32411717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Cyclophosphamide, dosage and duration not available
Number of subjects: 0
Study 32411845 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute passive exposure to e-cigarette emissions
Number of subjects: 40
Study 32411845 — intervention group
Group type: COMPARATOR
Intervention: Control session (no exposure)
Number of subjects: 40
Study 32411946 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP demand creation video
Number of subjects: 320
Study 32411946 — intervention group
Group type: COMPARATOR
Intervention: Having a primary partner
Number of subjects: 320
Study 32411946 — intervention group
Group type: COMPARATOR
Intervention: Being in a sexual partnership for <6 months
Number of subjects: 320
Study 32412142 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D sufficient group (serum 25OHD ≥ 20 ng/mL)
Number of subjects: 1308
Study 32412142 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficient group (serum 25OHD 10-20 ng/mL)
Number of subjects: 1308
Study 32412142 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficient group (serum 25OHD ≤ 10 ng/mL)
Number of subjects: 1308
Study 32412142 — intervention group
Group type: COMPARATOR
Intervention: Serum 25OHD < 20 ng/mL
Number of subjects: 1308
Study 32412142 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25OHD ≥ 20 ng/mL
Number of subjects: 1308
Study 32412989 — intervention group
Group type: EXPERIMENTAL
Intervention: TFA-1 sensor
Number of subjects: 37
Study 32412989 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger sensor
Number of subjects: 37
Study 32412989 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔVpeak
Number of subjects: 37
Study 32413298 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stimulation of visual cortex using a visual cortical prosthesis (VCP) to trace shapes on the surface of visual cortex.
Number of subjects: 0
Study 32414330 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer drug-eluting stent (BP-DES)
Number of subjects: 1400
Study 32414330 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer drug-eluting stent (DP-DES)
Number of subjects: 1400
Study 32414346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use food (RUF) provided according to WHO prescription weight- and age-bands for a maximum of 9-12 months.
Number of subjects: 173
Study 32414346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use food (RUF) provided according to WHO prescription weight- and age-bands.
Number of subjects: 173
Study 32414346 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with sub-optimal RUF intake at week 2.
Number of subjects: 173
Study 32414362 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear wave elastography (SWE) technology
Number of subjects: 0
Study 32414392 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplo-SCT
Number of subjects: 131
Study 32414392 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 131
Study 32414527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tack Endovascular System
Number of subjects: 201
Study 32414772 — intervention group
Group type: EXPERIMENTAL
Intervention: Early recognition and appropriate treatment
Number of subjects: 1
Study 32414772 — intervention group
Group type: EXPERIMENTAL
Intervention: Public awareness on dangerous allergic reactions
Number of subjects: 1
Study 32414772 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary preventative medicine and efficient therapeutic protocols
Number of subjects: 1
Study 32414827 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralised Chronic Medication Dispensing and Distribution (CCMDD) programme
Number of subjects: 55
Study 32414827 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic-based ART provision
Number of subjects: 55
Study 32414848 — intervention group
Group type: EXPERIMENTAL
Intervention: Entospletinib
Number of subjects: 12
Study 32414848 — intervention group
Group type: EXPERIMENTAL
Intervention: Entospletinib + Vincristine chemotherapy
Number of subjects: 12
Study 32414848 — intervention group
Group type: EXPERIMENTAL
Intervention: Entospletinib + Selumetinib
Number of subjects: 12
Study 32414850 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP)
Number of subjects: 31
Study 32414862 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 88
Study 32415575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 302
Study 32415575 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 302
Study 32415586 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated quantification of high signal intensity volumes using ultrashort echo-time MRI (%MR-HSV)
Number of subjects: 30
Study 32415586 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated quantification of low signal intensity volumes using ultrashort echo-time MRI (%MR-LSV)
Number of subjects: 30
Study 32415586 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated MR metrics
Number of subjects: 30
Study 32415586 — intervention group
Group type: EXPERIMENTAL
Intervention: %MR-TSV
Number of subjects: 30
Study 32415586 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation of %MR-HSV
Number of subjects: 30
Study 32415586 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproducibility of automated quantification
Number of subjects: 30
Study 32415705 — intervention group
Group type: COMPARATOR
Intervention: Direct oral anticoagulants (DOACs) - high-dose
Number of subjects: 47469
Study 32415705 — intervention group
Group type: COMPARATOR
Intervention: Direct oral anticoagulants (DOACs) - low-dose
Number of subjects: 47469
Study 32415705 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 47469
Study 32415708 — intervention group
Group type: EXPERIMENTAL
Intervention: HSK3486 (0.4 mg/kg)
Number of subjects: 0
Study 32415771 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study 32416231 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliviado Dementia Care-Hospice Edition training program
Number of subjects: 53
Study 32416231 — intervention group
Group type: COMPARATOR
Intervention: Pre-training assessment
Number of subjects: 53
Study 32416231 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-training assessment
Number of subjects: 53
Study 32416264 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasonography for sliding sign testing
Number of subjects: 86
Study 32416264 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative sliding sign and EFI historic factors score
Number of subjects: 86
Study 32416264 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative sliding sign with diagnosis of endometrioma
Number of subjects: 86
Study 32416715 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarthritis Physical activity Care Pathway (OA-PCP) intervention involving 3 physical activity coaching calls, three check-in emails, and linkage with community resources.
Number of subjects: 60
Study 32416715 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarthritis Physical activity Care Pathway (OA-PCP) intervention
Number of subjects: 60
Study 32416765 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32416764 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800CW 25 mg
Number of subjects: 11
Study 32416764 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800CW 50 mg
Number of subjects: 11
Study 32416764 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800CW 75 mg
Number of subjects: 11
Study 32416764 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800CW (all doses)
Number of subjects: 11
Study 32417327 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality imaging
Number of subjects: 0
Study 32417333 — intervention group
Group type: EXPERIMENTAL
Intervention: Active AL amyloidosis with cardiac involvement (active-CA)
Number of subjects: 45
Study 32417333 — intervention group
Group type: COMPARATOR
Intervention: Active AL amyloidosis without cardiac involvement (active-non-CA)
Number of subjects: 45
Study 32417333 — intervention group
Group type: EXPERIMENTAL
Intervention: AL amyloidosis with cardiac involvement in remission (remission-CA)
Number of subjects: 45
Study 32417337 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress cardiovascular magnetic resonance (CMR) imaging
Number of subjects: 0
Study 32417337 — intervention group
Group type: COMPARATOR
Intervention: Immediate x-ray coronary angiography (XCA)
Number of subjects: 0
Study 32417337 — intervention group
Group type: COMPARATOR
Intervention: No imaging
Number of subjects: 0
Study 32417337 — intervention group
Group type: COMPARATOR
Intervention: Single-photon emission computed tomography
Number of subjects: 0
Study 32417337 — intervention group
Group type: COMPARATOR
Intervention: Coronary computed tomographic angiography with selective computed tomographic fractional flow reserve
Number of subjects: 0
Study 32417369 — intervention group
Group type: EXPERIMENTAL
Intervention: FGFR3 genomic alterations (GAs)
Number of subjects: 112
Study 32417369 — intervention group
Group type: EXPERIMENTAL
Intervention: High FGFR3 activity
Number of subjects: 112
Study 32417369 — intervention group
Group type: EXPERIMENTAL
Intervention: lncRNA-FGFR3-active tumors
Number of subjects: 112
Study 32417369 — intervention group
Group type: EXPERIMENTAL
Intervention: High FGFR3 gene expression
Number of subjects: 112
Study 32417369 — intervention group
Group type: EXPERIMENTAL
Intervention: FGFR3 activity or mutation/fusion
Number of subjects: 112
Study 32417405 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 34
Study 32417537 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa (enzyme replacement therapy)
Number of subjects: 19
Study 32417924 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary portal of entry
Number of subjects: 545
Study 32417924 — intervention group
Group type: EXPERIMENTAL
Intervention: iha_17 virulence gene
Number of subjects: 545
Study 32417924 — intervention group
Group type: EXPERIMENTAL
Intervention: STc88
Number of subjects: 545
Study 32417924 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare-associated infections
Number of subjects: 545
Study 32417924 — intervention group
Group type: EXPERIMENTAL
Intervention: High Charlson comorbidity index
Number of subjects: 545
Study 32417924 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 545
Study 32418049 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp block
Number of subjects: 13
Study 32418049 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional pharmacological approach)
Number of subjects: 13
Study 32418051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 32418051 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 0
Study 32418051 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 32418051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (BRAF+ subgroup)
Number of subjects: 0
Study 32418142 — intervention group
Group type: EXPERIMENTAL
Intervention: < 12-month DAPT
Number of subjects: 2967
Study 32418142 — intervention group
Group type: COMPARATOR
Intervention: ≥ 12-month DAPT
Number of subjects: 2967
Study 32418251 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal calprotectin measurement by ELISA
Number of subjects: 121
Study 32418251 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal calprotectin measurement by immunochromatography
Number of subjects: 121
Study 32418251 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of species diversity and relative bacterial abundance profiles
Number of subjects: 121
Study 32418251 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic score of enteropathy
Number of subjects: 121
Study 32418478 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity index (sum of 14 noncardiac conditions)
Number of subjects: 373
Study 32418478 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression alone
Number of subjects: 373
Study 32418478 — intervention group
Group type: COMPARATOR
Intervention: Noncardiac comorbidities (other than depression)
Number of subjects: 373
Study 32418493 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD risk prediction model
Number of subjects: 572
Study 32418613 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Number of subjects: 0
Study 32418613 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 32418720 — intervention group
Group type: EXPERIMENTAL
Intervention: SVEAT score
Number of subjects: 321
Study 32418720 — intervention group
Group type: COMPARATOR
Intervention: HEART score
Number of subjects: 321
Study 32418720 — intervention group
Group type: COMPARATOR
Intervention: TIMI score
Number of subjects: 321
Study 32418717 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO biodegradable polymer sirolimus-eluting stent
Number of subjects: 2614
Study 32418771 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Number of subjects: 72
Study 32418789 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 vaccination (3 doses with a minimum of 1 month interval between treatment courses)
Number of subjects: 36
Study 32418789 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 36
Study 32418803 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting prolonged sedentary time for sleep
Number of subjects: 423
Study 32418803 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting total or prolonged sedentary for moderate-to-vigorous physical activity
Number of subjects: 423
Study 32418803 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting total or prolonged sedentary for light physical activity
Number of subjects: 423
Study 32418803 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting prolonged sedentary for short bouts
Number of subjects: 423
Study 32418803 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting total or prolonged sedentary with light physical activity
Number of subjects: 423
Study 32418803 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting with moderate-to-vigorous physical activity
Number of subjects: 423
Study 32418854 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 318
Study 32418854 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention
Number of subjects: 318
Study 32418854 — intervention group
Group type: COMPARATOR
Intervention: Angiographic presentation as intramural hematoma
Number of subjects: 318
Study 32419399 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 345
Study 32419586 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of antiplatelet therapy (APT) during noncardiac surgery
Number of subjects: 3582
Study 32419586 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of antiplatelet therapy (APT) during noncardiac surgery
Number of subjects: 3582
Study 32419679 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg/day, escalated to 80 mg/day after week 4 based on tolerability and clinical assessment of TD.
Number of subjects: 161
Study 32419820 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (AG)
Number of subjects: 45
Study 32419820 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture group (EG)
Number of subjects: 45
Study 32419820 — intervention group
Group type: COMPARATOR
Intervention: Sham group (SG)
Number of subjects: 45
Study 32419949 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bowel preparation (2L polyethylene glycol solution night before CE, 5mL simethicone and 5mg metoclopramide 20 minutes prior to CE, right lateral position 30 minutes after swallowing CE)
Number of subjects: 50
Study 32419949 — intervention group
Group type: COMPARATOR
Intervention: Control (no solid food after 7 p.m. night prior to CE, no liquids 4 hours prior to CE)
Number of subjects: 50
Study 32419950 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-based physical activity in Swedish participants
Number of subjects: 0
Study 32419950 — intervention group
Group type: COMPARATOR
Intervention: Device-based physical activity in Australian participants
Number of subjects: 0
Study 32419950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour in both countries
Number of subjects: 0
Study 32420402 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 302
Study 32420402 — intervention group
Group type: COMPARATOR
Intervention: Artemisinin-based combination therapies
Number of subjects: 302
Study 32420450 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional compression factor (CCF, 0.75 D)
Number of subjects: 99
Study 32420450 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased compression factor (ICF, 1.75 D)
Number of subjects: 99
Study 32420450 — intervention group
Group type: COMPARATOR
Intervention: Control group (spectacle-wearing)
Number of subjects: 99
Study 32420697 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 42
Study 32421208 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological galactagogues (domperidone, metoclopramide, sulpiride, thyrotropin-releasing hormone)
Number of subjects: 3005
Study 32421208 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 3005
Study 32421208 — intervention group
Group type: COMPARATOR
Intervention: Natural galactagogues (banana flower, fennel, fenugreek, ginger, ixbut, levant cotton, moringa, palm dates, pork knuckle, shatavari, silymarin, torbangun leaves or other natural mixtures)
Number of subjects: 3005
Study 32421208 — intervention group
Group type: COMPARATOR
Intervention: Natural galactagogues
Number of subjects: 3005
Study 32421437 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo LQTS variants (especially SCN5A variants)
Number of subjects: 39
Study 32421437 — intervention group
Group type: COMPARATOR
Intervention: Familial LQTS variants
Number of subjects: 39
Study 32421437 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature ventricular contractions
Number of subjects: 39
Study 32422174 — intervention group
Group type: EXPERIMENTAL
Intervention: Static fixation test
Number of subjects: 235
Study 32422174 — intervention group
Group type: EXPERIMENTAL
Intervention: 30sEpoch dynamic fixation test
Number of subjects: 235
Study 32422241 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-gated coronary computed tomography angiography (CCTA)
Number of subjects: 104
Study 32422241 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA considering non-evaluable segments as obstructive
Number of subjects: 104
Study 32423317 — intervention group
Group type: EXPERIMENTAL
Intervention: AF-ESUS score (integer-based point scoring system)
Number of subjects: 839
Study 32423317 — intervention group
Group type: EXPERIMENTAL
Intervention: Score of ≤0
Number of subjects: 839
Study 32423317 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the curve of the score
Number of subjects: 839
Study 32423376 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet to lymphocyte ratio (PLR) > 204.4
Number of subjects: 38
Study 32423376 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil to lymphocyte ratio (NLR) > 3.1
Number of subjects: 38
Study 32423376 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR combined with hs-cTnT or NT-proBNP
Number of subjects: 38
Study 32423376 — intervention group
Group type: COMPARATOR
Intervention: Patients with MACCE
Number of subjects: 38
Study 32423402 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention
Number of subjects: 158
Study 32423402 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal diagnosis
Number of subjects: 158
Study 32423402 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum depression scores (EPDS)
Number of subjects: 158